Time Required for Disappearance of Urate Crystals from Synovial Fluid After Successful Hypouricaemic Treatment Relates to the Duration of Gout

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2007 Jan 16

PMID 17223663

Citations 36

Authors

Eliseo Pascual

Francisca Sivera

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine whether hypouricaemic treatment results in the disappearance of urate crystals from gouty joints and to define the time required.

Methods: In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample. The sample was then analysed for the presence of MSU crystals, and the number of crystals/400x field was noted. SUA levels and the duration of gout were also noted.

Results: MSU crystals disappeared from the SF of all 18 joints after reduction of SUA to normal levels. The time required for disappearance ranged from 3 to 33 months; disappearance time correlated with the duration of gout (r(s) = 0.71; p<0.01). The median number of MSU crystals in the SF samples before urate-lowering treatment was 7.5 (2.5-11) crystals/400x field, reducing to 3 (1-6.5) crystals/400x field (p<0.05) at 3 months. Crystal counts continued to decrease after 3 months.

Conclusions: In gout, reduction of SUA to normal levels results in disappearance of urate crystals from SF, requiring a longer time in those patients with gout of longer duration. This indicates that urate crystal deposition in joints is reversible. Normalisation of SUA levels results in a decrease in the concentration of MSU crystals in SF in the asymptomatic gouty joints. This may partially explain the reduced frequency of gouty attacks when a patient has been treated with SUA-lowering drugs.

Citing Articles

Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority....

Peeters I, den Broeder A, Taylor W, den Broeder N, Flendrie M, van Herwaarden N Trials. 2023; 24(1):282.

PMID: 37072799 PMC: 10114395. DOI: 10.1186/s13063-023-07242-y.

The Hong Kong Society of Rheumatology consensus recommendations for the management of gout.

Yip R, Cheung T, So H, Chan J, Ho C, Tsang H Clin Rheumatol. 2023; 42(8):2013-2027.

PMID: 37014501 PMC: 10345000. DOI: 10.1007/s10067-023-06578-9.

Critical appraisal of serum urate targets in the management of gout.

Stamp L, Dalbeth N Nat Rev Rheumatol. 2022; 18(10):603-609.

PMID: 35974164 DOI: 10.1038/s41584-022-00816-1.

Testing Topical Products Specifically to Reduce Inflammatory Pain from Gout: Transdermal NSAID Delivery and Monosodium Urate Solubility.

Hooper M, He L J Pain Res. 2022; 15:1825-1835.

PMID: 35791391 PMC: 9250783. DOI: 10.2147/JPR.S367536.

Dietary supplements for chronic gout.

Andres M, Sivera F, Buchbinder R, Pardo J, Carmona L Cochrane Database Syst Rev. 2021; 11:CD010156.

PMID: 34767649 PMC: 8589461. DOI: 10.1002/14651858.CD010156.pub3.

References

Perez-Ruiz F, Calabozo M, Pijoan J, Herrero-Beites A, Ruibal A . Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47(4):356-60. DOI: 10.1002/art.10511. View

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T . Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2007; 67(7):960-6. PMC: 2564789. DOI: 10.1136/ard.2007.076232. View

Riedel A, Nelson M, Joseph-Ridge N, Wallace K, Macdonald P, Becker M . Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004; 31(8):1575-81. View

Pascual E . Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991; 34(2):141-5. DOI: 10.1002/art.1780340203. View

Yu T, GUTMAN A . Principles of current management of primary gout. Am J Med Sci. 1967; 254(6):893-907. DOI: 10.1097/00000441-196712000-00019. View

Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P . Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999; 131(10):756-9. DOI: 10.7326/0003-4819-131-10-199911160-00007. View

Pascual E, Jovani V . Synovial fluid analysis. Best Pract Res Clin Rheumatol. 2005; 19(3):371-86. DOI: 10.1016/j.berh.2005.01.004. View

Beutler A, Rull M, Schlesinger N, Baker D, Hoffman B, Schumacher Jr H . Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Clin Exp Rheumatol. 2001; 19(5):595. View

Loebl W, SCOTT J . Withdrawal of allopurinol in patients with gout. Ann Rheum Dis. 1974; 33(4):304-7. PMC: 1006262. DOI: 10.1136/ard.33.4.304. View

10.

Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E . Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?. J Rheumatol. 2001; 28(3):577-80. View

11.

Shoji A, Yamanaka H, Kamatani N . A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004; 51(3):321-5. DOI: 10.1002/art.20405. View

12.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E . Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998; 57(9):545-9. PMC: 1752740. DOI: 10.1136/ard.57.9.545. View

13.

Pascual E, Jovani V . A quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with gout. Br J Rheumatol. 1995; 34(8):724-6. DOI: 10.1093/rheumatology/34.8.724. View

14.

Pascual E, Castellano J . Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol. 1992; 19(4):600-3. View

15.

Lumbreras B, Pascual E, Frasquet J, Gonzalez-Salinas J, Rodriguez E, Hernandez-Aguado I . Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis. 2005; 64(4):612-5. PMC: 1755440. DOI: 10.1136/ard.2004.027268. View

16.

Yu T, GUTMAN A . Mobilization of gouty tophi by protracted use of uricosuric agents. Am J Med. 1951; 11(6):765-9. DOI: 10.1016/0002-9343(51)90028-9. View